• Can We 'Switch Off' Type 1 Diabetes?

News & Views

Can We 'Switch Off' Type 1 Diabetes?

Feb 17 2016

Modern medicine never ceases to amaze, but the concept of simply ‘switching’ off Type 1 diabetes brings a completely different level of wow factor. Developed by a team of researchers at the Massachusetts Institute of Technology (MIT), the revelation could mean diabetes suffers could soon say goodbye to the daily routine of injecting themselves with insulin. Instead, a transplant of insulin-producing beta cells made from human stem cells could offer effective, long term relief. When tested on mice, the cells were able to ‘switch off’ diabetes for up to six months.

Following in the footsteps of Harvard

The advancement comes in the wake of recent research from a team at Harvard University, that used human embryonic stem cells to develop a bona fide cure. After mass transforming human embryonic stem cells into hundreds of millions of beta cells, the team transplanted them into a hyperglycemic mouse. From the word go, they actively started to reduce the rodent’s blood sugar levels.

Unfortunately, the experiment wasn’t without its challenges. The mouse’s defective immune system eventually destroyed the new beta cells which rendered them useless. The MIT team has channelled months of research in addressing this barrier, and now believes that it’s found a way to ‘hide’ the insulin-producing beta cells from the self-destructive Type 1 diabetes immune system.

Hiding cells from a suicidal immune system

They did this by encasing the transplanted beta cells in a brown algae derived gel. They then modified the chemical structure of the alginate capsules to strengthen the shield.

“We made all these derivatives of alginate by attaching different small molecules to the [large molecule] chain,” explains Arturo Vegas, lead author of the study. The idea was to develop an alginate derivative that was armed with “the ability to prevent recognition by the immune system.”

Finally, they struck gold with the triazole-thiomorpholine dioxide (TMTD) variant. This effectively hid beta cells from their white blood cell counterparts, leaving them free to produce insulin and reduce blood sugar for up to 174 days.  

Next up, human trials. Whether or not the concept applies to the human body is yet to be seen, however scientists are optimistic that this could transform life for Type 1 diabetes.

While change is on the horizon, until it arrives diabetes suffers will continue to rely on insulin injections. ‘Easing the way for pain-free insulin injections’ offers more insight into how the process works, and the steps that are being taken to minimise the pain associated with these vital injections.

Image via Flickr Creative Commons. Photo credits: Dennis Skley
 


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

Lab Indonesia

Apr 24 2024 Jakarta, Indonesia

Expomed Eurasia

Apr 25 2024 Istanbul, Turkey

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

InformEx Zone at CPhl North America

May 07 2024 Pennsylvania, PA, USA

View all events